Ceri Bygrave

518 total citations
18 papers, 167 citations indexed

About

Ceri Bygrave is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ceri Bygrave has authored 18 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 13 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Ceri Bygrave's work include Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (11 papers) and Peptidase Inhibition and Analysis (4 papers). Ceri Bygrave is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (11 papers) and Peptidase Inhibition and Analysis (4 papers). Ceri Bygrave collaborates with scholars based in United Kingdom, United States and Spain. Ceri Bygrave's co-authors include Jonathan Kell, Brendan Healy, Neil D. Evans, Rosemary A. Barnes, P. Lewis White, Martin Kaiser, Faith E. Davies, Roger G. Owen, Matthew Jenner and Gareth J. Morgan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ceri Bygrave

16 papers receiving 166 citations

Peers

Countries citing papers authored by Ceri Bygrave

Since Specialization

Citations

This map shows the geographic impact of Ceri Bygrave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ceri Bygrave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ceri Bygrave more than expected).

Fields of papers citing papers by Ceri Bygrave

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ceri Bygrave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ceri Bygrave. The network helps show where Ceri Bygrave may publish in the future.

Co-authorship network of co-authors of Ceri Bygrave

This figure shows the co-authorship network connecting the top 25 collaborators of Ceri Bygrave. A scholar is included among the top collaborators of Ceri Bygrave based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ceri Bygrave. Ceri Bygrave is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network 2024 ·Blood ·Michael Rückert, (unknown), Mamta Garg, Ceri Bygrave, (unknown), (unknown), Kristina Bardenheuer, (unknown), Morten Salomo, (unknown), (unknown), (unknown), Joris Diels, Vladimír Maisnar, Ivan Špıčka, Roman Hájek	0
2	Challenges in designing and running smouldering myeloma interventional clinical trials 2024 ·SHILAP Revista de lepidopterología ·(unknown), Eileen M. Boyle, (unknown), Lydia Lee, Dean Smith, Ceri Bygrave, Karthik Ramasamy, Kwee Yong	1
3	Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper 2024 ·British Journal of Haematology ·Martin Kaiser, Guy Pratt, Ceri Bygrave, Kristian M. Bowles, Simon Stern, Matthew Jenner	3
4	Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper 2024 ·British Journal of Haematology ·Martin Kaiser, Vicky Goh, Simon Stern, (unknown), Neil Rabin, Karthik Ramasamy, (unknown), Richard Soutar, John Ashcroft, Guy Pratt, Christina Messiou, Ceri Bygrave	3
5	Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series 2024 ·SHILAP Revista de lepidopterología ·(unknown), Margaret Bowers, (unknown), A. J. CHARLTON, (unknown), Jonathan Cullis, (unknown), David Donaldson, Mary Drake, (unknown), (unknown), Jane Tighe, Ceri Bygrave, (unknown)	0
6	Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis 2024 ·British Journal of Haematology ·Jahanzaib Khwaja, (unknown), Maria Atta, Ceri Bygrave, Adam Forbes, (unknown), (unknown), James G. Taylor, (unknown), (unknown), Charles Crawley, (unknown), Rachel M. Brown, Richard Soutar, Mamta Garg, Andrzej Rydzewski, Krzysztof Jamroziak, Shameem Mahmood, Ashutosh Wechalekar	5
7	Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma 2023 ·Blood ·Emma Searle, James Cavet, (unknown), Steven Knapper, Ceri Bygrave, Dima El‐Sharkawi, Charlotte Pawlyn, Maria Creignou, Harriet S. Walter, David Valcárcel, (unknown), Jenny O’Nions, (unknown), (unknown), (unknown), Neil Pegg, (unknown), (unknown), (unknown), Tim C. P. Somervaille	1
8	P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 2023 ·HemaSphere ·Emma Searle, Jim Cavet, Steven Knapper, Ceri Bygrave, (unknown), Dima El‐Sharkawi, Charlotte Pawlyn, Maria Creignou, Harriet S. Walter, David Valcárcel, (unknown), (unknown), (unknown), Neil Pegg, (unknown), (unknown), (unknown), Tim C. P. Somervaille	1
9	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>) 2021 ·Haematologica ·Kwee Yong, Samantha Hinsley, Holger W. Auner, Ceri Bygrave, Martin Kaiser, Karthik Ramasamy, Ruth M. de Tute, (unknown), Louise Flanagan, Mamta Garg, Stephen Hawkins, Catherine Williams, Jamie Cavenagh, Neil Rabin, (unknown), Gareth J. Morgan, Faith E. Davies, Roger G. Owen, Sarah Brown	8
10	Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM). 2021 ·Journal of Clinical Oncology ·Kwee Yong, (unknown), William Wilson, (unknown), Matthew Streetly, Jonathan Sive, Ceri Bygrave, Michael A. Chapman, Ruth de Tute, Selina J Chavda, Elizabeth H. Phillips, (unknown), (unknown), Richard G. Jenner, (unknown), (unknown), James D. Cavenagh, Laura Clifton‐Hadley, Roger G. Owen, Rakesh Popat	4
11	Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience 2020 ·Leukemia & lymphoma ·(unknown), Bhuvan Kishore, Matthew Jenner, Kevin Boyd, (unknown), Sarah Bird, (unknown), R.L. Robinson, Grant Vallance, Mark Offer, Jaimal Kothari, Andy Peniket, (unknown), (unknown), (unknown), Ceri Bygrave, Karthik Ramasamy	5
12	Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma 2020 ·British Journal of Haematology ·Ceri Bygrave, Charlotte Pawlyn, Faith E. Davies, (unknown), David A. Cairns, Anna Hockaday, Matthew Jenner, Gordon Cook, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gareth J. Morgan, Graham Jackson, Martin Kaiser	27
13	Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia 2020 ·British Journal of Haematology ·Joanna Zabkiewicz, (unknown), (unknown), Ceri Bygrave, Nader Omidvar, (unknown), Steven Knapper, Carol Guy, Robert K. Hills, Alan K. Burnett, Caroline Alvares	3
14	Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study 2018 ·Blood ·Kwee Yong, Samantha Hinsley, (unknown), (unknown), Sarah Brown, Louise Flanagan, Catherine Williams, Jamie Cavenagh, Martin Kaiser, Neil Rabin, Karthik Ramasamy, Mamta Garg, Holger W. Auner, (unknown), Ceri Bygrave, Ruth M. de Tute, Gareth J. Morgan, Faith E. Davies, Roger G. Owen	4
15	Risk of relapse of multiple myeloma following kidney transplantation 2018 ·Clinical Kidney Journal ·Sapna Shah, Maria Ibrahim, Michael P. Delaney, Steve Schey, Ceri Bygrave, Matthew Streetly, Reuben Benjamin	16
16	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study 2017 ·Blood ·Kwee Yong, Samantha Hinsley, Holger W. Auner, (unknown), Ruth M. de Tute, Sarah Brown, Louise Flanagan, C. Rosie Williams, Jamie Cavenagh, Martin Kaiser, Neil Rabin, Karthik Ramasamy, Mamta Garg, (unknown), Ceri Bygrave, Gareth J. Morgan, Faith E. Davies, Roger G. Owen	6
17	Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients 2008 ·Journal of Clinical Pathology ·Rosemary A. Barnes, P. Lewis White, Ceri Bygrave, Neil D. Evans, Brendan Healy, Jonathan Kell	71
18	The value of biochemical and ultrasound measurements in predicting pregnancy outcome in women with a history of recurrent miscarriage 1998 ·Human Reproduction ·Tin Chiu Li, Philipp Spring, Ceri Bygrave, Susan Laird, (unknown), (unknown), O. A. Adekanmi	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact